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Abstract
Drug-induced liver injury (DILI) is a rare but potentially life
threatening adverse drug reaction. DILI may mimic any
morphologic characteristic of acute or chronic liver disease,
and the histopathologic features of DILI may be indistinguish-
able from those of other causes of liver injury, such as acute
viral hepatitis. In this review article, we provide an update on
causative agents, clinical features, pathogenesis, diagnosis
modalities, and outcomes of DILI. In addition, we review
results of recently reported genetic studies and updates on
pharmacological and invasive treatments.
© 2015 The Second Affiliated Hospital of Chongqing Medical
University. Published by XIA & HE Publishing Ltd. All rights
reserved.
Introduction
Drug-induced liver injury (DILI) is the most frequent indica-
tion for drug withdrawal from the pharmaceutical market due
to its association with significant adverse effects, morbidity,
and mortality. Several drugs have been removed from
the market because of DILI, including bromfenac and
troglitazone.1 DILI may be divided into intrinsic and idiosyn-
cratic hepatotoxicity, and idiosyncratic injury is further
divided into allergic and nonallergic reaction. The intrinsic
mechanism is related to dose dependent hepatotoxicity,
whereas idiosyncratic hepatotoxicity is not dose dependent
and may happen in an unpredictable fashion. Allergic idiosyn-
cratic hepatotoxicity is further characterized by the presence
of symptoms and signs typical of an adaptive immune system
reaction, including fever, skin reactions, eosinophilia, forma-
tion of autoantibodies, and a short latency time particularly
after re-exposure.
DILI is responsible for the majority of acute liver failure
cases and is now the leading cause for liver transplantation
among patients.2 Among hospitalized patients with jaundice,
2–10% of cases are reported to be secondary to liver injury
caused by drugs. Furthermore, DILI is responsible for approx-
imately 10% of all adverse drug reactions in the United States
(USA).3 Estimates of the incidence of DILI are reported to be
as high as 14–24 cases/100,000 individuals, and estimates
show that nearly 44,000 patients per year will develop DILI.4
Two prospective surveys of the general population of
France and Spain estimated DILI incidence to be 7–14/
100,000 people,5 and retrospective studies from Sweden
and the United Kingdom (UK) reported an estimated DILI
incidence rate of 2–3/100,000 people per year.6 The true
incidence of DILI is still largely unknown due to underreport-
ing of adverse drug reactions. Moreover, the presence of
confounding factors makes it difficult to determine an accu-
rate DILI incidence. Nonetheless, the World Health Organiza-
tion (WHO) proclaimed an increasing incidence of DILI since
the 1990s.7
Clinical presentation
The clinical presentation of DILI ranges from asymptomatic
abnormal liver function tests to acute and chronic hepatitis.8
DILI is classified based on the Council for International
Organizations of Medical Sciences (CIOMS), as hepatocellu-
lar, cholestatic, or mixed injury.9 Approximately 25–30% of
patients who develop DILI display symptoms of an allergic
drug reaction, such as fever, rash, and eosinophilia.10
Although rare, DILI was implicated in the development of
cirrhosis in the long-term follow-up of patients after initial
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presentation of DILI.11 Notwithstanding, DILI is often a self-
limiting process without chronic consequences, as some pa-
tients may need hospitalization, and some may progress to
acute liver failure resulting in a high mortality rate. Many
drugs can cause DILI, and different drugs have led to varying
disease time courses (usually, the resolution of cholestatic
liver injury is slower than hepatocellular injury).12
Physicians must be aware of time differences in the pro-
gression of DILI. For example, trovafloxacin and amoxicillin-
clavulanic acid can have a lag period of 2–3 weeks between
the discontinuation of treatment and the development of
idiosyncratic liver injury, as evidenced by elevated liver
enzymes.13 Depending on several factors, there is wide
variability in DILI symptoms, time course, and type of
liver injury.
Pathogenesis
DILI can be mediated by two mechanisms: intrinsic liver
injury and idiosyncratic liver injury. Drugs that cause intrinsic
liver injury exert hepatotoxic effects either directly by the
agent itself or indirectly by its metabolite. In these instances,
liver injury is dose dependent. An example of a drug that leads
to intrinsic liver injury is acetaminophen. Idiosyncratic hep-
atotoxicity is the DILI mechanism that develops from the
majority of the DILI causing agents. Idiosyncratic liver injury
can be caused by metabolic or immunological mechanisms,
with the immunological effect resulting from a hypersensitiv-
ity reaction. Idiosyncratic liver injury is generally associated
with hepatocellular inflammation, while intrinsic liver injury is
associated with necrosis and minimal inflammation. Recently,
some reports addressed the role of other mechanisms of liver
injury, including the role of mitochondrial injury and active
drug metabolites in the pathogenesis of DILI. These other
mechanisms need further characterization.14
The majority of DILI cases are due to idiosyncratic adverse
drug reactions, which can involve the liver and other organs,
including skin and bone marrow. Five basic theories were
developed to explain idiosyncratic drug reactions. These
include drug metabolism, the hapten hypothesis, the inflam-
magen model, the danger hypothesis, and pharmacological
interaction.15 The large number of theories, different target
organs and cells involved in the injury, the diversity of
mechanisms involved, and different risk factors limit the de-
velopment of a simple approach to prevent and predict idio-
syncratic DILI. One constant aspect for drugs that cause
intrinsic liver injury and drugs with well-documented idiosyn-
cratic DILI is a dose-dependent component.16
Although DILI is often related to idiosyncratic reactions,
there are other factors that substantially increase the risk of
developing idiosyncratic DILI, including genetic susceptibility,
older age, environmental factors, female sex, the presence of
concomitant diseases, polypharmacy, dosage and duration
of treatment, drug formulation, concomitant alcohol con-
sumption, nutritional status (obesity and malnutrition),
pre-existing chronic liver disease, and other underlying co-
morbidities.17 Most idiosyncratic drug reactions occur roughly
between 1–2 weeks and 2–3 months from the start of drug
therapy.18 However, there are numerous exceptions describ-
ing exposure of a drug for many months prior to DILI, such as
in cases of liver injury resulting from nitrofurantoin and
ximelagatran.19
In many instances, the liver plays an important role in the
metabolism and detoxification of drugs, and drugs that are
predominantly metabolized by the liver are more frequently
associated with hepatic adverse effects than drugs with
limited or nonsignificant hepatic metabolism.20 The most
common drugs in the USA leading to idiosyncratic DILI are
antimicrobials, central nervous system drugs, herbal/dietary
supplements, and immunomodulatory agents.21 However,
other drugs, including nonsteroidal anti-inflammatory drugs
(NSAIDs) and anticoagulation medications, are associated
with idiosyncratic DILI. In an extensive analysis of 461 DILI
cases over a 10 year period involving 505 drugs, the anti-
infective drugs were found to be most frequently associated
with idiosyncratic DILI, with amoxicillin-clavulanate account-
ing for 12.8% of these cases.10
Despite the complexity of the mechanism underlying DILI,
a three step working model has been proposed for its patho-
genesis: 1. drugs, or their metabolites, cause cell stress
directly (intrinsic pathway); 2. Immune reactions are trig-
gered; 3. Apoptotic or necrotic cell death, depending on the
availability of adenosine triphosphate, is initiated.22 Despite
this model, the exploration of the mechanism of DILI remains
challenging and is at the forefront of research in the field of
hepatotoxicity.
Factors associated with increased susceptibility to
DILI
1- Genetic susceptibility
The occurrence of DILI is associated with genetic vulnerabil-
ity, and multiple studies have focused on the exploration of
single nucleotide polymorphisms (SNP) within transporter
genes.4 A small study series linked polymorphisms in CYP2C9
and CYP2C19 to DILI.23 However, a large Spanish study on
DILI patients showed that polymorphisms in these isoforms
were not associated with increased susceptibility to DILI, and,
based on those findings, genetic variation in CYP2C9 and
CYP2C19 may not be considered a DILI risk factor.24
CYP2D6, another gene with allelic variants and encoding
enzymes with variable degrees of activity, is associated with
the development of hepatotoxicity after use of certain
pharmaceutical agents, including antidepressants and
herbal products.25
A potential link was also found between the CYP2E1
genotype and risk for developing DILI. Specifically, the wild-
type CYP2E1 genotype is associated with increased suscept-
ibility to DILI, specifically when antituberculosis medications
are administered.26 However, other studies did not demon-
strate this association.27 Finally, polymorphic variants of the
CYP2B6 gene are associated with ticlopidine-induced liver in-
jury in association with the HLA-A*3303 haplotype in Japa-
nese patients.28
Uridine 5’-diphospho-glucuronosyltransferase (UGT) has
an important role in metabolism and is linked to the develop-
ment of DILI. UGT catalyzes glucuronidation reactions, which
aid in the detoxification of drugs and endogenous compounds,
such as bilirubin and bile acids. Many isoforms of UGT are
known, and they are encoded by 19 different genes in
humans.29 UGT1A1 is involved in bilirubin metabolism, and
mutations found in the UGT1A1 gene are responsible for Gil-
bert’s syndrome and hyperbilirubinemia. Drugs that are me-
tabolized by the enzyme expressed by UGT1A1, such as
irinotecan, estradiol, and buprenorphine or drugs that inhibit
its function, such as indinavir and ketoconazole, have an in-
creased risk for hepatotoxicity in patients with a mutant
100 Journal of Clinical and Translational Hepatology 2015 vol. 3 | 99–108
Khoury T. et al: Drug induced liver injury, cause, diagnosis and treatment
UGT1A1 genotype.30 Another polymorphic isoform of UGT,
UGTB7, is associated with DILI induced by diclofenac by
increasing glucuronidation activity.31
Mutations in GST mu 1 (GSTM1) and GST theta 1 (GSTT1),
other hepatocyte enzymes involved in metabolism and
detoxification, may lead to partial deletion, absence of
enzymatic activity, and predisposition to DILI.32
In addition, MDR3 (ABCB4), MRP2 (ABCC2), and BSEP
(ABCB11) are ABC transporters located at the canalicular
hepatocyte membrane and are associated with DILI. Muta-
tions in ABCB4 were described in a patient with hepatocellular
DILI following the administration of amoxicillin-clavulanic
acid and in a patient with cholestatic DILI after taking
risperidone.33 Mixed type of DILI associated with mutations
in ABCC2 were seen in Korean patients and a mutation of
ABCB11 was linked with both drug-induced hepatocellular
and drug-induced cholestatic liver injury.34
The SLC transporter, OATP1B1, responsible for the influx of
many drugs, was shown to have a connection to hepatotox-
icity after administration of specific pharmaceuticals, includ-
ing troglitazone, rifampin, bosentan, methotrexate, and
statins.35 Polymorphisms in the SLCO1B1 gene were de-
scribed in cases of drug hypersensitivity. For instance, several
SNPs identified in this gene resulted in altered function, which
affected levels of statins, methotrexate, and irinotecan and
may lead to severe drug toxicities.36
Allelic variations of manganese superoxide dismutase
(MnSOD), which is involved in the defense against cellular
oxidative stress, were shown to possibly increase the sus-
ceptibility for DILI, particularly with antituberculosis drugs.37
These variations increased the risk for developing cholestatic
and mixed types of DILI from drugs and their metabolites in
Spanish patients.38 Increased levels of MnSOD are also
thought to cause accumulation of hydrogen peroxide, which
may lead to the occurrence of DILI.
Althoughmany polymorphisms have been identified within
CYP450, there is no strong evidence demonstrating a corre-
lation between specific CYP genotypes and DILI. Only a few
polymorphisms are associated with hepatotoxicity. Another
example of genetic variation leading to DILI susceptibility is
mutations in NAT2 (N-acetyl transferase 2), in which some
variants were identified as slow or rapid acetylators. Isonia-
zid, an antituberculosis drug, is initially metabolized by NAT2
prior to oxidation by CYP2E1. Although some felt that rapid
acetylators caused isoniazid-induced liver necrosis in the
past,39 subsequent studies have indicated a strong correla-
tion between slow acetylators and hepatotoxicity caused by
antituberculosis drugs.40 While genetic factors have been
connected to DILI, further research is needed to delineate
the exact role that specific genetic mechanisms play in DILI.
2- Adaptive immunological mechanisms
The adaptive immune system is thought to be involved
mechanistically in idiosyncratic DILI, as shown by the pres-
ence of immune cells in liver biopsies of DILI patients and by
the association of DILI with allergic symptoms. It is hypothe-
sized that either the drug metabolite or parent drug binds to
hepatic proteins to form a neoantigen and activates the
immune system to generate antibodies against the hepatic
proteins.41 This mechanism was established with diclofenac-
induced liver injury.42 Furthermore, autoantibodies against
the CYP450 enzymes were reported in cases of DILI; these
include ingestion of halothane, tienilic acid, dihydralazine,
and anticonvulsant drugs.43
Another mechanism thought to involve the immune
system in the pathogenesis of DILI is the p-I concept, which
suggests that the drug itself directly stimulates T cells.44 The
p-I mechanism was originally proposed for sulfamethoxa-
zole.45 Despite evidence for a role of the immune system in
the pathogenesis of DILI, its function in the progression of
DILI is unclear because of the natural liver tolerance to anti-
gens from ineffective stimulation of T cells by hepatic antigen
presenting cells.46
3- Drug-drug interaction and hepatic metabolism
The risk of idiosyncratic DILI is generally increased with
higher doses of a medication and a dose of more than
50 mg daily, especially if the drug is known to have extensive
hepatic metabolism. This increased risk is attributed to the
generation of reactive intermediaries and subsequent meta-
bolic idiosyncrasy. Furthermore, oral drugs that undergo
hepatic metabolism of more than 50% are associated with
increased liver adverse effects, greater incidence of DILI, and
increased morbidity and mortality as compared to medica-
tions that undergo less than 50% hepatic metabolism.20
4- Underlying disease
Liver disease is an important factor in the development of
both intrinsic and idiosyncratic DILI, as abnormal liver func-
tion alters the expression of drug transporter proteins, not
only in the liver but also in other organs.47 Moreover, under-
lying liver disease can change the pharmacokinetics of drugs
and lead to unexpected effects. It is difficult to predict the
action of drugs in patients with liver diseases and, hence,
follow-up of serum drug levels and dose adaptations should
be performed carefully.48
The outcomes and risk for DILI in patients with known
chronic liver disease and in whom potential hepatotoxic drugs
are used were reviewed previously.49 The presence of pre-
existing liver disease does not definitively increase the sus-
ceptibility to DILI, and most drugs can be used safely in these
patients.50 Still, it is important to remember that a diseased
liver with reduced functional capacity and diminished reserve,
limits the liver’s ability to recover and could worsen the con-
sequences of DILI.51 Finally, nonalcoholic fatty liver disease
(NAFLD) in both rats and humans was shown to lead to mi-
tochondrial dysfunction, which can significantly increase the
risk of DILI.52
Role of hepatitis viruses
Viral hepatitis predisposes patients to the development of
DILI in certain situations. Nader et al. reported an increased
risk for DILI in hospitalized patients positive for hepatitis C
virus receiving treatment with rifampicin, isoniazide, and pyr-
azinamide for tuberculosis (8.8% of the 534 patients devel-
oped DILI).53 Furthermore, hepatitis C virus infection is a risk
factor for increased severity of acetaminophen-induced acute
liver injury.54 Another study showed that the presence of hep-
atitis B virus surface antigen was a moderate predictor of DILI
but with low precision.55 Conversely, a third study concluded
that viral hepatitis does not appear to be an established risk
factor for INH hepatotoxicity, except in those who are injec-
tion drug users.56 Patients treated with antiretrovirals for
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human immunodeficiency virus (HIV) infection have a higher
risk of severe hepatotoxicity when coinfected with the hepa-
titis B or C viruses, particularly if the regimen is based on
protease inhibitors.57 Nonetheless, there is no increase in DI-
LI occurrence in those treated with other antiviral agents.
Thus, the presence of viral hepatitis is not a well-established
risk factor for the occurrence of DILI.
Classification of liver injury
The clinical spectrum of liver injury in DILI is classified
according to the Council for International Organizations of
Medical Sciences (CIOMS).58 Hepatocellular DILI is estab-
lished once there is an isolated elevation of alanine amino-
transferase (ALT) greater than two times the upper limit of
normal, or when the ratio between ALT to alkaline phospha-
tase (ALK) is more than five. However, if the ratio of ALT to
ALK is below two, the liver injury is classified as cholestatic
DILI. A ratio of ALT to ALK between two and five is classified as
mixed liver injury.
Diagnosis
The absence of specific signs and symptoms and the lack of
specific criteria and testing make the diagnosis of DILI
difficult. The diagnosis of DILI is often one of exclusion
(Fig. 1). The manifestations of drug hepatotoxic effects are
highly variable, ranging from asymptomatic liver enzymes ab-
normality to fulminant hepatic failure. Thus, diagnosis of DILI
must be based on a comprehensive clinical assessment, in-
cluding the temporal association between illness and admin-
istration of a causative drug. A pattern of liver injury, which is
characteristic of the drug, is also helpful for diagnosis as well
as exclusion of other causes of acute liver injury.
One of the most difficult issues in the diagnosis of DILI is
the determination of causality. There are three main ap-
proaches to assess causality.59 The gold standard approach
is a positive rechallenge test, which is similar to Koch’s postu-
lates. However, this approach is not pursued, as it is clinically
dangerous. The second method, the ad hoc approach, is also
not commonly used. The third, and most widely used, ap-
proach is the Roussel Uclaf Causality Assessment Method
(RUCAM) scale. This method, demonstrated 86% sensitivity,
89% specificity, and positive and negative predictive values of
93% and 78%, respectively.60 RUCAM is a semiquantitative
scale, and it contains seven domains, including: onset and
ending of the injury after initiation or discontinuation of the
suspected agent; progression and course of the reaction; risk
factors; concomitant medications; causes of liver injury other
than drugs; previous information on the medication; and
Fig. 1. Algorithm for drug induced liver injury (DILI) diagnosis. ALT, alanine aminotransferase; ALP, alkaline phosphatase; CMV, cytomegalovirus; EBV, Epstein-Barr
virus; HCV, hepatitis C virus; HBV, hepatitis B virus, HEV, hepatitis E virus, HSV, herpes simplex virus; MRCP, magnetic resonance cholangiopancreatography;
EUS, endoscopic ultrasound; TIBC, total iron binding capacity; HIV, human immunedeficiency virus.
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response to readministration, if any. This score assesses cau-
sality through assigning a score (ranging between −3 and +3
points) to each domain. The overall score ranges from −5 to
+14. A score greater than eight for an implicated drug sug-
gests a highly probable relationship between the drug and
liver injury. Other scores include probable (6–8), possible
(3–5), unlikely (1–2), or excluded (<0).60
Maria and Victorino (M&V) developed another DILI scoring
system in 1997. This system, which is a more simplified
scoring system, still uses some components of RUCAM and is
referred to as the Clinical Diagnostic Scale or the M&V scale.
The overall score includes five levels: definite, probable,
possible, unlikely, and excluded. The M&V scale is not
commonly used because of limitations, particularly the clas-
sification of ‘definite’ only in cases of positive rechallenge and
the presence of hypersensitivity features.10 Recently, a third
diagnostic scoring has been developed in Japan, the Digestive
Disease Week-Japan (DDW-J) scale. This scale was also de-
rived from the RUCAM scale, but the DDW-J scale is more
accurate than the RUCAM and M&V scales in the diagnosis
DILI.61 This scale includes important criteria, such as the in
vitro drug lymphocyte stimulation test (DLST). Nonetheless,
due to the DLST and lack of standardization, this scale is not
frequently used outside of Japan. Further evaluation of the
DLST and other lymphocyte-based tests in relation to DILI is
needed because of the proposed role of the adaptive immune
system in the pathogenesis of DILI.62
Despite the development of scoring systems and scales in
the evaluation of DILI, DILI is still a diagnosis of exclusion.
The definite diagnosis of DILI is supported by the exclusion of
other causes of liver injury, such as autoimmunity and viral
hepatitis.63 Recently, an international DILI expert team re-
viewed a diagnostic system, and a consensus was established
regarding the threshold for defining DILI. The team assigned
standardization criteria for the pattern of liver injury severity,
chronicity, and assessment of causality. Furthermore, the
consensus set an approach to define DILI in the setting of
chronic liver disease.64 In addition, the Food and Drug Admin-
istration (FDA) proposed guidelines for prediction of severe
serious DILI as follows: ALT greater than eight times the
upper limit of normal, ALT greater than five times the upper
limit of normal for 2 weeks, ALT greater than three times the
upper limit of normal in association with serum bilirubin
greater than two times the upper limit of normal, more than
1.53 prothrombin time-international normalized ratio (INR),
or symptoms of liver injury. In these cases, the guidelines
predict severe hepatotoxicity and recommend discontinua-
tion of the culprit drug.65
Liver histology in the diagnosis of DILI
The role of a liver biopsy in the diagnostic work-up of DILI is
controversial since there are no unique histological findings of
DILI on liver histology. The histological features of DILI can
mimic any form of liver injury that is not DILI induced.66
Although some histological features, such as abundance of
eosinophils and neutrophils, granulomatous hepatitis, and
hepatocyte necrosis in the perivenular location, and choles-
tasis with hepatitis might suggest DILI, overlap exists with
many other acute and chronic liver diseases; and no patho-
gnomonic features confirm the diagnosis of DILI.67 The ab-
sence of portal inflammation with the presence of necrosis in
the centrilobular area is relatively characteristic of DILI, but
this can still be seen histologically in acute onset autoimmune
hepatitis. Currently, no reports address the importance of
liver biopsy in causality assessment, but liver histology can
be considered compatible with DILI.21 In early studies of
DILI, histology was considered to be important. However,
the advances in methodologies to rule out potential etiolo-
gies, such as viral infections, autoimmune diseases, hemo-
chromatosis, and Wilson’s disease, and better imaging
techniques have decreased the need for a biopsy. Further-
more, if the patient demonstrates a rapid improvement in
liver tests following cessation of drug therapy, a routine liver
biopsy is not indicated.68
Liver biopsy may be helpful when underlying liver disease
and/or autoimmune hepatitis is suspected despite negative
serological biomarkers. Biopsy can also be used if the
suspected agent causing DILI has not been reported previ-
ously to cause liver injury or in cases where there is very slow
regression or other chronic liver disease. Furthermore, liver
biopsy can reveal histological characteristics specific for
certain drugs, e.g. steatohepatitis with amiodarone or val-
proate69 or nodular regenerative hyperplasia with azathio-
prine and 6-thioguanine.70 However, the impact of knowing
unusual histological patterns on management is uncertain,
and there is limited data on the impact of histology on clinical
outcomes in DILI. Moreover, studies have shown that there
are some histological features that may be present uniformly
in DILI cases, such as the presence of portal tract expansion
by infiltration of mononuclear cells and eosinophills, centrizo-
nal cholestasis, and focal necrosis.71 Ramachandran et al.
reported a variety of specific histological patterns induced
by various medications.72 Recently, a review of liver histopa-
thology in 249 patients in the Drug-Induced Liver Injury
Network (DILIN) indicated that five liver injury patterns were
responsible for 83% of the cases.73 Poorer outcomes were
associated with higher degrees of necrosis, microvesicular
steatosis, and a ductular involvement, whereas the presence
of intrahepatic eosinophils and/or granulomas was more con-
sistent with a better prognosis. The prognostic use of these
histological features is consistent with prior reports. The role
of routine liver biopsy in the diagnosis of DILI is still unclear,
and in most instances it is not recommended during the early
stages of diagnosis. Liver biopsy is certainly indicated in cases
where there is no improvement of liver function or when a
diagnosis other than DILI is suspected. Additional prospective
studies are needed to delineate the role of liver histology in
defining and diagnosing DILI.
The role of new serum biomarkers in DILI
Ongoing research efforts seek to identify new biomarkers for
DILI; several proposed biomarker include serum liver injury
markers (glutathione S-transferase a, sorbitol dehydro-
genase (SDH)) and hepatocyte mitochondrial dysfunction
marker (glutamate dehydrogenase). Moreover, the discov-
ery of circulating serum microRNAs has shown novel tissue
specificity of miR-122 and miR-192 for liver injury. Further-
more, serum full-length keratin-18 (K-18) and high mobility
group box protein 1 (HMGB-1) have been shown to be a
sensitive biomarker for necrosis and cell death, but neither
of them is liver specific. M-30 is a serum protein that
selectively recognizes caspase cleaved neoepitopes of K-18
released from hepatocytes undergoing apoptotic death,
while serum M-65 reflects total hepatocyte death (apoptosis
and necrosis).74,75 Recently, the combination of serum M-30
levels with other laboratory parameters was shown to be
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superior to the King’s College criteria and Model for End-
Stage Liver Disease (MELD) score in predicting spontaneous
survival in acute liver failure.76 Furthermore, DILI secondary
to acetaminophen overdose was shown to elevate levels of
serum biomarkers of SDH, glutamate dehydrogenase, and
HMGB-1.77 A panel of these early biomarkers for DILI was
recently tested in patients presenting to the hospital after an
acetaminophen overdose with initially normal serum liver
enzymes levels.78 Poorer outcome in acetaminophen
overdose was associated with elevated level of acetylated
HMGB-1.79 Several studies have shown that detection of
acetaminophen protein adducts in serum can confirm a
diagnosis of acetaminophen hepatotoxicity.
The role serum proteomics in DILI
Currently, the proteins or pathways involved in the patho-
genesis of DILI can be further studied with advanced bio-
informatics software. The serum proteomic characteristics of
74 patients in DILIN who had a serum sample collected
2 weeks before the onset of DILI compared to 40 healthy
controls were analyzed.80 Several proteins were highly ele-
vated in subjects with hepatocellular versus cholestatic DILI,
including fructose-bisphosphate aldolase B. This protein was
correlated with serum aminotransferases levels at baseline
and returned to normal during follow-up. Interestingly, auto-
antibodies to this protein have previously been reported
in patients with troglitazone hepatotoxicity.81 Moreover,
elevated levels of apolipoprotein E, which is a lipoprotein
contained in chylomicrons rich triglyceride, was the major
proteome used in distinguishing patients with DILI from
controls. A proteomics platform in combination with metabo-
lomics was recently used to distinguish patients who devel-
oped ximelagatran hepatotoxicity from unaffected controls.82
This data suggested that proteomics might aid in the
diagnosis of DILI and guide exploration of causative agents
involved in DILI. Thus, further proteomic studies are indicated
in this field.
The role of serum cytokines, chemokines and miRNAs
in DILI
Serum chemokines and cytokine levels may also be useful
biomarkers for diagnosis and prognosis of DILI.83 Recently,
the DILIN measured 27 immune analytes in 78 subjects with-
in 2 weeks of DILI onset and after 6 months.84 This analysis
identified decreases in interleukin-9 and interleukin-17 and
platelet-derived growth factor serum albumin as predictors
of early death, suggesting a role for these serum biomarkers
in the pathogenesis of DILI. These data are consistent with
recent studies showing a role of the Th17 adaptive immunity
pathway in the pathogenesis of idiosyncratic DILI.85 However,
there was no difference in the serum level of interleukin-17 in
patients with acute liver failure due to idiosyncratic DILI and
those with acetaminophen overdose.86
MicroRNAs (miRNAs) are small noncoding RNA molecules
(about 22 nucleotides in length) found in plant, animals, and
some viruses that function in RNA silencing and posttranscrip-
tional regulation of gene expression. They can be detected in
microvesicles in the serum. Although a number of miRNAs are
widely expressed, certain miRNAs appear to be tissue specific.
miRNAs specifically expressed in the liver include miR-122,
miR-21, and miR-192. Liver-derived miRNAs may represent
specific biomarkers of acetaminophen-induced DILI. However,
early in the course of livery injury, these miRNAs are
elevated.87 In addition, they appear to have a prognostic role
when considering liver transplant in acetaminophen hepato-
toxicity.88 Given their liver tissue specificity, assay quantifi-
cation availability, and short half-life, these miRNAs are
important biomarkers for severe acute liver injury.
Pharmacogenomics into the pathogenesis of DILI
Human leukocyte antigen (HLA) is the locus for genes that
encode highly polymorphic proteins on the surface of the cells
that are responsible for regulating the immune system in
humans. A growing number of other immunological reactions,
including dermatologic reactions and idiosyncratic DILI, have
also been associated with various HLA alleles.89 In most in-
stances, there are a series of drug-protein modifications that
produce an intermediate or reactive metabolite that is essen-
tial for forming the immunogenic hapten. Hapten then binds
the antigen binding location on HLA. Recently, different HLA
susceptibility alleles to carbamazepine hypersensitivity in
Chinese and European subjects were reported.90 Since HLA
polymorphisms are restricted to each ethnicity, the absence
of a particular genetic susceptibility to DILI in one patient
population ethnicity does not necessarily exclude a positive
association in another group population.
Treatment
DILI has a wide range of manifestations, from silent bio-
chemical abnormalities to severe fulminant hepatitis with
jaundice. Liver injury secondary to DILI often improves
following discontinuation of the suspected offending drug.
There also may be spontaneous regression of liver injury
without discontinuation of the causative drug. Therefore, the
discontinuation of a drug should be carefully evaluated, in
consideration of the significance of the medication and the
degree of damage being caused by its administration.91 The
association of transaminase elevation in combination with
clinical jaundice, secondary to the administration of drugs,
was associated with serious liver injury and poor prognosis
(fatality rate of 10% for many drugs).92 Due to those findings
of increased mortality, Hy’s law for monitoring and estimating
the severity of DILI was developed. HY’s law includes eleva-
tion of liver enzymes (aspartate aminotransferase (AST) or
ALT more than 3 times upper limit of normal (ULN) or ALP
more than 1.5 times ULN) in combination with elevated bilir-
ubin (more than 3 times ULN) at any time after starting a new
drug. If HY’s law is met, it predicts severe liver injury; and
termination of drug use is recommended. However, two re-
cent studies have shown that the mortality rate is high in
patients with DILI and jaundice even after the discontinuation
of the suspected agents.10 The predicted mortality in Hy’s law
has been confirmed by several international studies in
Sweden, Spain, and the USA, which demonstrated a 9–12%
rate of mortality or liver transplantation in patients who de-
veloped severe DILI with jaundice.93 Once DILI is suspected
or identified, management begins with the prompt discontin-
uation of the suspected agents along with supportive mea-
sures and monitoring. There are no reports of beneficial
therapies, other than the use of N-acetylcysteine for acetami-
nophen-induced liver injury.94 Empiric use of corticosteroids
in acute liver failure due to DILI is not recommended due to
the lack of benefit in previously reported studies but is still
sometimes used in patients with severe DILI.95 Steroid
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therapy may be useful in DILI cases associated with hyper-
sensitivity features, such as is the case with carbamazepine-
induced hepatotoxicity.95 Furthermore, steroids also exert
beneficial effects in the treatment of drug-induced autoim-
mune hepatitis, such as nitrofurantoin and minocycline.96
In two acute liver failure trials, which included 104 patients
and 12 patients with DILI, steroids failed to demonstrate any
benefit. Moreover, in those trials, patients in the steroid
treatment group tended to have a worse prognosis.97 A re-
cent retrospective study of 300 patients who were hospital-
ized with DILI showed that combination treatment with
ursodeoxycholic acid (UDCA) and oral steroids was beneficial
for nonacetaminophen DILI with acute liver failure. The com-
bination therapy had a significantly positive effect on resolu-
tion and recovery time and prognosis.98
Antioxidants have been used for the treatment of severe
DILI, and, specifically, N-acetylcysteine (NAC) is considered
the treatment of choice for acetaminophen-induced liver
injury.99 The benefits of NAC in nonacetaminophen DILI has
still yet to be elucidated. In one trial that included 173 pa-
tients with nonacetaminophen liver injury, the administration
of continuous intravenous NAC over 3 days was not associ-
ated with improved survival. However, a subset of patients
with early stage mild acute liver injury did show an increased
rate of spontaneous improvement and better prognosis.100
In another study, intravenous NAC was beneficial in the treat-
ment of acute liver failure secondary to idiosyncratic DILI
other than paracetamol.101
Plasma exchange is another therapeutic modality that
had been used for the treatment of acute liver failure. The
mechanism of this modality lies in the removal of toxins that
accumulate in hepatic failure and the addition of coagulation
factors to correct the coagulopathy from liver injury.102 Multi-
ple studies have shown the efficacy of plasma exchange in
reducing the level of nitrogenous waste products (ammonia
and urea), improving coagulopathy, and improving encephal-
opathy in patients with acute liver failure.103 Other studies
have demonstrated that plasma exchange exerts beneficial
effects on survival in acute liver failure secondary to acetami-
nophen DILI and in patients with residual liver functional
capacity.104 In acute liver failure, other benefits stem from
the removal of inflammatory cytokines and effects on regu-
latory T cells.105 Therefore, plasma exchange exerts positive
prognostic and survival value over symptomatic treatment
alone in cases of acute liver failure secondary to DILI. Still,
other studies have shown that plasma exchange has only
minor survival benefits on patients with pre-existing chronic
liver disease.106
Molecular adsorbents recirculatory systems (MARS) and
fractionated plasma separation and adsorption (PFSA) are
advanced treatment options in cases of hepatic failure,
although they have no beneficial survival effect in randomized
control trials (RCTs) of patients with acute and chronic liver
failure.107,108 Even though plasma exchange may be superior
to MARS and PFSA in removing cytokines, MARS and PFSA
have decreased risk of infections and allergic reactions.109
Thus, plasma exchange may be preferable for the support of
fulminant hepatic failure due to its capacity to remove inflam-
matory cytokines and protein bound toxic molecules, specif-
ically in patients with acute liver failure without pre-existing
chronic liver disease. Although treatment options in DILI are
limited, UDCA does have a positive effect on DILI, particularly
in cases of cholestatic injury, by protecting hepatocytes from
the toxic effects of bile acids.110
In order to provide adequate supportive care and man-
agement in acute fulminant hepatic failure (including from
DILI), patients should be cared for in the setting of an
intensive care unit in a liver transplant center. Once acute
liver failure develops, liver transplantation may be the sole
treatment option.111
The course and the natural history of DILI after the
acute episode: does DILI lead to chronic liver disease?
The progression of acute liver injury from DILI to chronic liver
disease and liver cirrhosis has been reported with different
drugs.112 A prospective study on Spanish patients revealed
the development of chronic liver injury in 6% of patients fol-
lowed for a period of 20 months after initial DILI. In this study,
chronic liver injury was defined by the presence of abnormal
liver function tests for more than 3 months after DILI onset.
Drugs most commonly associated with chronic liver disease
were amoxicillin/clavulanate, bentazepam, and atorvastatin.
Patients with a cholestatic liver injury pattern were more sus-
ceptible to progress to chronic liver injury.113 Similar results
were shown among Swedish patients, as only three out of 50
(6%) patients who presented with DILI had persistently ab-
normal liver tests after a median follow-up of 48 months.114
The long term consequences of DILI was further evaluated
in a study that followed patients for a period of 10 years, and
the progression of DILI to significant liver disease after severe
DILI was rare. Twenty-three out of 685 (3%) DILI patients
were hospitalized for liver disease during the study period,
and five out of 685 patients had liver-related mortality. Eight
patients developed liver cirrhosis, and among those eight
patients, five cirrhotic patients did not have other known
causes of liver disease other than the past episode of DILI.
The patients who developed liver-related morbidity and
mortality had longer duration of therapy with the suspected
DILI causing agent.11
Prognosis
DILI patients with asymptomatic and mild disease are ex-
pected to recover completely. In addition, most patients with
symptomatic DILI are expected to recover after discontinua-
tion of the causative drug. With supportive care most patients
will not have residual clinical, laboratory, radiological, or
histological evidence of liver disease.93 A favorable prognosis
for recovery is expected in the majority of patients with DILI.
For example, in one cohort, 712 of 784 (91%) DILI patients
with jaundice recovered.93 Conversely, patients with severe
DILI associated with acute liver failure and concomitant coa-
gulopathy and encephalopathy had a poor prognosis115. Even
though the incidence of DILI is more common in males,
females tend to develop a more severe course of DILI, leading
to acute decompensated liver failure. The prognosis of
acetaminophen-induced DILI treated by N-acetylcycsteine is
better than the prognosis of DILI from other drugs. Although
most of the patients recover from DILI, there are patients
who develop chronic liver disease, with the incidence of
developing chronic DILI in one Spanish registry reported to
be 6%.113
Patients who fulfill Hy’s Law and patients with a predom-
inant cholestatic type of DILI have a worse prognosis and
increased mortality.10,93 The presence of eosinophilic hepatic
infiltration with peripheral eosinophilia has a positive prog-
nostic value in DILI,116 as demonstrated in a Spanish study
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that showed that eosinophilia was more common in patients
who recovered from DILI. In that study, approximately 5% of
the patients who died or underwent liver transplantation had
peripheral eosinophilia, while 23% eosinophilia was seen in
patients who recovered.10 Once DILI patients develop or
present with coagulopathy and encephalopathy, the progno-
sis is very poor, with approximately 60–80% mortality in
the absence of liver transplantation.117 Furthermore, an
improvement of liver enzymes is not always predictive of
an improved prognosis, as the reduction of serum liver
enzymes might herald poor prognostic value due to massive
hepatocyte death.118
Scoring systems have been developed to assess which
patients are candidates for liver transplantation in hepatic
disease. The model for end-stage liver disease (MELD) score,
which is based on bilirubin, serum creatinine, and INR, can
be used to predict the short term mortality rate among
acetaminophen-induced liver injury.119 A second score, the
King’s College Hospital Criteria for fulminant hepatic failure
in both acetaminophen and nonacetaminophen-induced
acute liver failure, is used to identify candidates for liver
transplantation.120 In addition, recent radiological assess-
ment scores of hepatic volume by computed tomography
(CT) can be helpful in predicting prognosis in DILI patients.121
Conclusions
DILI remains one of the most common causes of acute liver
failure and is a challenging clinical entity due to the lack of
specific diagnostic and prognostic markers. The pathogenesis
of DILI is diverse and genetic susceptibility may play a role in
the development of DILI, especially idiosyncratic DILI. The
clinical spectrum of DILI is complex, and, although DILI is still a
diagnosis of exclusion, diagnostic accuracy may be improved
by using causality assessment scores. The various histological
patterns of DILI reported in studies and the lack of specific
histological characteristics of DILI also contribute to the
difficulty in diagnosing DILI. Finally, the basis of treatment in
DILI is discontinuation of the suspected causative agent and
supportive measures. If signs of hypersensitivity are present,
then evidence supports the use of steroids. Further RCTs are
needed to identify definite biomarkers for the diagnosis of DILI
and to explore the role of specific treatments.
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